Edward Aloysius Sullivan Jr. - 04 Jan 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role: Director
Signature: /s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol: CMRA
Transactions as of: 04 Jan 2023
Transactions value $: $16,249
Form type: 4
Filing time: 06 Jan 2023, 15:14:27
Previous filing: 14 Feb 2023
Next filing: 16 Feb 2023
SEC: View on sec.gov

This filing has been restated, see here for the amended filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CMRA	Common Stock	Award	$13.5K	+11K	+126.4%	$1.23	19.7K	04 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CMRA	Warrants (right to buy)	Award	$2.74K	+11K		$0.25	11K	04 Jan 2023	Common Stock	22K	$1.23	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 10,979 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.
F2	The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.

Content

The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 10,979 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.

The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.